Darren Lehrich
Vice President of Investor Relations

[Audio Gap] percent and same-store revenue growth in our behavior was up about 7%. And we've commented that there's a bit of a stronger contribution from pricing, and we had some seasonal factors that impacted our volume in the quarter. I think if you think about those seasonal factors, primarily weaker flu on the acute care side and then a little bit of weather disruption on the behavioral side. And excluding some of those factors, I think we were right in the 2% range from a volume perspective in both segments.

Pricing growth in the quarter included core growth. We put that at around 3% and the benefit of funding from some of the Medicaid supplemental programs that were approved last year. We had a a $133 million year-over-year increase in those payments.

So given all the sort of focus on the increase in those Medicaid supplemental payments, we've been getting this question a lot. What was the core growth. And I think just to sort of give you the headline, we would put it at around down $20 million or so, so down around 3% -- and that math exercise essentially is we had a $15 million headwind related to the exchanges that we -- it was part of our guidance that we reaffirmed.

We had about a $30 million impact split between behavioral and acute on the seasonal factors related to flu and respiratory. We had about a $5 million impact for the readiness for the California staffing regulation that begins in June. And then